Advertisement


Paolo A. Ascierto, MD, on Metastatic Melanoma: Ipilimumab Study Results

2016 ESMO Congress

Advertisement

Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori–Fondazione Pascale, discusses overall survival and safety results from a phase III trial of ipilimumab at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma. (Abstract 1106O)



Related Videos

Bladder Cancer

Sumanta K. Pal, MD, on Urothelial Cancer: Results From the CheckMate 275 Trial

Sumanta K. Pal, MD, of the City of Hope, discusses phase II findings on the efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer who have received prior treatment. Follow him on Twitter: @montypal

Kidney Cancer

Alain Ravaud, MD, PhD, on RCC: Results of the S-TRAC Trial

Alain Ravaud, MD, PhD, of Bordeaux University Hospital, discusses phase III findings on sunitinib vs placebo as adjuvant treatment for high-risk renal cell carcinoma after nephrectomy. (Abstract LBA11)

Colorectal Cancer

Derek J. Jonker, MD, on Colorectal Cancer: Results From the CCTG/AGITG CO.23 Trial

Derek J. Jonker, MD, of The Ottawa Hospital Cancer Centre, discusses phase III study findings on napabucasin vs placebo in patients with pretreated advanced colorectal cancer. (Abstract 454O)

Gynecologic Cancers

Susana N. Banerjee, MBBS, PhD, on Ovarian Cancer: Results of the CORAL Trial

Susana N. Banerjee, PhD, MBBS, of The Royal Marsden NHS Foundation Trust, discusses phase II findings on abiraterone in patients with recurrent epithelial ovarian cancer. (Abstract LBA33)

Prostate Cancer

Christopher J. Sweeney, MBBS, on Localized Prostate Cancer: Metastasis-Free Survival as a Surrogate for Overall Survival

Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses how this early clinical endpoint will accelerate the development of new therapies for localized intermediate and high-risk prostate cancer. (Abstract 717O)

Advertisement

Advertisement




Advertisement